Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Vanderbilt University Medical Center
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
39Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02897063CT.gov Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Multiple System Atrophy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Midodrine (this asset) | Vanderbilt University Medical Center | P1 | CCC · 52 |
| Droxidopa | Loma Linda University | P3 | BB |
| Zoledronate | California Pacific Medical Center Research Institute | P4 | BB |
| Ioflupane | GE Healthcare | P3 | B |
| Ath-434 | Alterity Therapeutics | P2 | B |
| Riluzole | King's College London | P3 | B |
| Fipamezole | Juvantia Pharma Ltd | P2 | CCC |
| Exidavnemab | BioArctic AB | P2 | CCC |
| Carbidopa | Daniel Claassen | P1/2 | CCC |
+31 more in the Multiple System Atrophy cohort
Other indications for Midodrine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Spontaneous Periodic Hypothermia | — | P4 | BB · 71 |
| Quadriplegia | — | P4 | BB · 71 |
| Kidney Failure | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Midodrine in Multiple System Atrophy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/midodrine-multiple-system-atrophy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →